AXO-AAV-GM2

N/A

Report date: 2025/09/03 20:01:14

Base Information

Drug NameAXO-AAV-GM2
Drug Alias NameAXO-AAV-GM2 ProgramAXO AAV GM2AXO-AAV-GM2
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionBeta-hexosaminidase subunit alpha gene transferenceBeta-hexosaminidase subunit beta gene transference
TargetsBeta-hexosaminidase subunit alphaBeta-hexosaminidase subunit beta
Therapy Area/IndicationsTay-Sachs DiseaseSandhoff Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Massachusetts Medical School
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Massachusetts Medical SchoolSio Gene Therapies Inc
Active IndicationsN/A
Inactive IndicationsTay-Sachs DiseaseSandhoff Disease

Other Information

ATC CodeN/A
Related LinksN/A